<![CDATA[Pirtobrutinib Earns Approval in China for CLL/SLL Across All Therapy Lines]]>
China’s National Medical Products Administration (NMPA) has approved the non-covalent BTK inhibitor pirtobrutinib (Jaypirca) as a treatment for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) across all lines of therapy …